氘可来昔替尼(Deucravacitinib)服用注意事项？

Deucravacitinib can be used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy. The combined use of Deucravacitinib with other potent immunosuppressants is not recommended. Evaluate patients for active and latent tuberculosis (TB) infection before initiating treatment with Deucravacitinib. If positive, initiate TB treatment before starting Deucravacitinib. In addition, the following points should be noted when using deuterated colexitinib:

1. Hypersensitivity reactions, such as angioedema, have been reported in subjects receiving deuterated colexitinib. If a clinically significant hypersensitivity reaction occurs, initiate appropriate treatment and discontinue Deucravacitinib.

2. Avoid use in patients with active or severe infections. Consider the risks and benefits of treatment with deuterated colexitinib in patients with chronic or recurrent infections, previous exposure to tuberculosis, a history of serious or opportunistic infections, or underlying medical conditions that may predispose them to infection.

Monitor patients closely for signs and symptoms of infection during and after treatment with Deucravacitinib. Patients who develop a new infection during treatment with colexitinib should receive prompt and complete diagnostic testing; appropriate antimicrobial therapy should be initiated; and the patient should be monitored closely. If a patient develops a serious infection, interrupt deuterated colexitinib therapy. Do not restart deuteroclaxitinib treatment until the infection has resolved or been adequately treated.

3. For patients with a past history of latent or active TB (pulmonary tuberculosis) and for whom an adequate course of treatment cannot be confirmed, consider anti-tuberculosis treatment before starting Deucravacitinib treatment. Monitor patients receiving colexitinib for signs and symptoms of active TB during treatment.

4. Before initiating or continuing treatment with deucravacitinib, consider the benefits and risks for the individual patient, especially patients with known malignancies (other than successfully treated non-melanoma skin cancers) and patients who develop malignancies while receiving deucravacitinib.

5. Cases of rhabdomyolysis have been reported in subjects receiving Deucravacitinib, resulting in interruption or discontinuation of Deucravacitinib dosing. Discontinue deuterated colexitinib if a significant increase in CPK levels occurs or myopathy is diagnosed or suspected. Promptly report any unexplained muscle pain, tenderness, or weakness during treatment, especially if accompanied by malaise or fever.

6. Evaluate liver enzymes in patients with known or suspected liver disease at baseline and thereafter, consistent with routine patient management. If treatment-related liver enzyme elevations occur and drug-induced liver injury is suspected, interrupt treatment with Deucravacitinib until the diagnosis of liver injury is ruled out.

7. Before initiating treatment with Deucravacitinib, consider completing all age-appropriate immunizations according to current immunization guidelines, including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients receiving deuterated colexitinib.

Recommended related articles: